查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1498370

臨床試驗用品市場評估：依服務類型、依類型、依治療領域、依階段、依最終用戶、依地區、機會、預測，2017-2031 年

Clinical Trial Supplies Market Assessment, By Service Type, By Type, By Therapeutic Area, By Phase, By End-user, By Region, Opportunities and Forecast, 2017-2031F
出版日期: | 出版商: Market Xcel - Markets and Data | 英文 220 Pages | 商品交期: 3-5個工作天內

價格

2024-2031年預測期內，全球臨床試驗用品市場規模將以7.97%的複合年增長率擴大，從2023年的30.1億美元增至2031年的55.6億美元。該市場近年來取得了顯著的成長，預計未來將保持穩定的擴張速度。

臨床試驗是藥物開發的重要步驟，開發商透過臨床試驗確認藥物的安全性和有效性。在將任何藥物或化學產品投放市場之前，必須執行此步驟，以確保公共安全。技術進步、人口成長、慢性病盛行率增加、臨床試驗需求增加、藥品和化學產品需求增加以及確保患者安全的監管要求不斷提高等因素正在推動市場大幅成長。此外，業界正在看到智慧型設備的推出，這些設備可以提供準確、快速的發現來幫助研究和開發。公司和從業者共同努力，為行業專業人士帶來最好的技術。公共和商業組織都在籌集資金並大力投資以提供高品質的解決方案。這些巨頭公司在開發和推出新產品時採用聯盟、投資和併購等策略策略。

本報告調查了全球臨床試驗用品市場，並提供了市場概況，以及依服務類型、類型、治療領域、階段、最終用戶、地區和進入市場的公司劃分的趨勢。

目錄

第一章研究方法

第 2 章專案範圍與定義

第 3 章執行摘要

第 4 章 2017-2031 年全球臨床試驗用品市場展望

  • 市場規模與預測
  • 依服務類型
  • 依類型
  • 依治療領域
  • 愛別
  • 依最終用戶
  • 依地區
  • 各公司的市佔率 (%)，2023 年

第 5 章 2017-2031 年全球臨床試驗用品市場前景（依地區）

  • 北美
  • 歐洲
  • 亞太地區
  • 南美洲
  • 中東/非洲

第 6 章市場地圖，2023 年

第七章宏觀環境與產業結構

  • 需求與供給分析
  • 匯入/匯出分析
  • 價值鏈分析
  • PESTEL 分析
  • 波特五力分析

第 8 章市場動態

第 9 章創新/新興科技

第十章主要參會企業狀況

第 11 章案例研究

第 12 章主要進入者展望

  • Thermo Fisher Scientific Inc.
  • Catalent Inc.
  • Eurofins Scientific
  • Marken
  • Parexel
  • ICON plc
  • Almac Group Limited
  • Biocair International Limited
  • Sharp Services, LLC
  • Syneos Health

第 13 章策略建議

第十四章查詢及免責聲明

Product Code: MX11494

Global clinical trial supplies market is projected to witness a CAGR of 7.97% during the forecast period 2024-2031, growing from USD 3.01 billion in 2023 to USD 5.56 billion in 2031. The market has experienced significant growth in recent years and is expected to maintain a strong pace of expansion in the coming years.

Clinical trial is an essential step in developing any drug through which the developers ensure the safety and efficacy of any drug. This step is mandatory for any drug or chemical product before its launch to ensure public safety. The market is growing manifold due to factors such as advancing technology, increasing population and cases of chronic diseases, increasing need for clinical trials, increasing demand for drugs and chemical products and the rising regulatory requirements to ensure patient safety. Additionally, the industry has seen the launch of smart devices that provide precise and quick findings that are helpful in research and development. Companies and practitioners are collaborating to provide the best technology for industry professionals. Both public and commercial organizations are raising money and investing a sizable sum of it to be able to provide quality solutions. These massive corporations use strategic maneuvers like collaborations, investments, and mergers and acquisitions when they are striving to develop or introduce a new product. For instance, a strategic partnership between ICON plc (Ireland) and LEO Pharma (Denmark) was formed in March 2023 to improve LEO Pharma's clinical trial operations, emphasizing cost-effectiveness and patient-centricity.

Thermo Fisher Scientific Inc. (US) and the National Minority Quality Forum (NMQF), an independent non-profit organization devoted to research and education, partnered in September 2023. The goal of this partnership, which is made possible by NMQF's Alliance for Representative Clinical Trials (ARC), is to increase the participation of patient groups who have historically been underrepresented in clinical research.

Growing Need for Clinical Trials Fuels Market Growth

Clinical trials are essential for expanding our understanding of medicine, assessing novel cures, and enhancing patient care. The expanding number of registered trials reflects the increased interest in medical research, the creation of novel treatments, and the understanding of the significance of evidence-based medicine. According to the United States National Library of Medicine, there are 452,604 studies registered on Clinicaltrials.gov, with locations in all 50 states and 221 countries worldwide. The quick development of medical research and technology is one of the main causes of the rise in registered clinical trials. New research directions have been made possible by identifying novel disease targets, advancements in the knowledge of molecular mechanisms, and developments in fields such as immunology, regenerative medicine, and genomics. As a result, there has been a significant increase in the creation of innovative treatments and interventions, increasing the demand for clinical studies to assess their efficacy and safety.

Furthermore, the public, researchers, and healthcare professionals are becoming more aware of the value of evidence-based medicine.

A methodical and thorough way to assess the effectiveness and safety of medical therapies is through clinical trials. More academics and organizations are conducting clinical trials in response to the growing need for evidence-based medicine to produce high-quality data that can inform medical decisions and enhance patient outcomes. Moreover, the rise of registered trials can also be attributed to the globalization of clinical research. Clinical trials used to be mostly carried out in industrialized nations. Nonetheless, there has been a notable change in the direction of conducting trials in other geographical areas, such as developing and emerging markets. As of May 17, 2023, clinicaltrials.gov reports 140,268 registered studies overall. However, there have been about 240,844 registered studies in countries apart from the United States. Numerous variables are driving this increase, including easier access to larger patient populations, a wider range of genetic origins, lower prices, and quicker regulatory pathways. Consequently, many clinical trials have been filed in areas previously underrepresented in medical research, driving market growth.

Rising Regulatory Requirements to Ensure Patient Safety

The market for clinical trials is expanding due to the need for safety evaluations of novel drugs and compounds. Strict regulatory requirements requiring thorough toxicity studies serve as the driving force for these assessments. Modern technological developments like organ-on-a-chip models and high-throughput screening have eliminated the practice of animal research. It has been demonstrated that these novel models improve the accuracy and relevance of the predictions in the tests. Furthermore, because of the increased safety concerns surrounding high-profile medication withdrawals, thorough safety assessments have become increasingly necessary throughout the drug development process. In addition to saving money and time, in-vitro testing contributes to the healthy expansion of the biotechnology and pharmaceutical industries by enabling the creation of safer and more effective therapeutic agents to meet the growing incidence of chronic diseases and aging populations.

For example, Parexel International Corp, a global clinical research organization (CRO) that focuses on the discovery and delivery of innovative new therapies to enhance patient health, announced the development of a new clinical trial supply and logistics depot in Suzhou, China, in September 2022. This well-placed facility provides quick access to supplies and investigational therapeutics for delivery to clinical locations and patients worldwide for domestic and foreign biopharmaceutical companies conducting clinical studies.

Thermo Fisher Scientific Inc. stated in October 2022 that it will increase operations in Kentucky to assist clients by providing patients with life-altering medications. The current facility offers biomarker and central lab services, giving biopharma customers access to top-notch lab work to expedite the drug development. Additionally, this has increased the company's global visibility and allowed it to grow its diagnostics business throughout the globe.

Growth in Demand for Biologics to Fuel Market Growth

Biologics and biosimilars are manufactured using extremely intricate procedures from living cells, and their market share is predicted to increase steadily because of growing research into biotechnology and genetics, including the development of biosimilar products and nanoparticle-based drug delivery systems. Biologics, which include hormones, blood products, vaccines, genes, insulin, and monoclonal antibody (mAb) products, are being used as the most cutting-edge treatments for autoimmune illnesses such as rheumatoid arthritis and Crohn's disease. Over the projected time, biologics have grown significantly due to their growing demand and clinical benefits. For instance, five biosimilars were approved by the Center for Drug Evaluation and Research (CDER) in 2023, three of which were biosimilars for reference products for which there was no prior biosimilar. For 14 reference products, CDER has authorized 45 biosimilars so far. Several products were authorized as interchangeable biosimilars, which can be interchanged for the reference product at a pharmacy, like generics that are substituted subject to state law. CDER has approved seven interchangeable biosimilars.

The number of cancer cases is rising quickly, and researchers are becoming more innovative in their approaches to using biologics for treating cancer. In an article published in January 2022 by the American Cancer Society Journal, the number of cancer cases reported has gone up to approximately 1.9 million in the United States in 2022. Biologics therapy is becoming more popular than standard cancer treatment because it uses the body's natural immune systems and healing capabilities to either combat cancer or repair healthy tissue following treatment. Therefore, more cancer cases fuel biologics expansion, so the biologics segment is predicted to expand significantly.

North America to Dominate the Clinical Trial Supplies Market

The increasing number of clinical trials is why North America has the largest global market for clinical trial supplies. The North American clinical trial supply industry is driven by rising government funding, increasing disease prevalence, and a growing number of clinical trials. Since more large-scale pharmaceutical R&D clinical trials are carried out in this region, many CROs and biopharmaceutical businesses have established their headquarters in the United States and Canada. The most efficient regulation of clinical trials with advanced therapy, including electronic records and signatures, protection of human subjects, and good clinical practices for non-clinical laboratory studies, eases the process of conducting clinical trials overall. Significant R&D investments are being made due to high cancer prevalence in the United States, another factor propelling North America's clinical trial supply market.

According to the cancer facts and figures report for 2023 from the American Cancer Society, approximately 1.9 million new cancer cases were diagnosed in 2023. Notably, prostate cancer is projected to lead with an estimated 288,300 cases, followed by lung cancer with 238,340 cases, and female breast cancer with 300,590 cases. Similarly, data released by the Government of Canada in May 2022 revealed that around 233,900 Canadians received cancer diagnoses in 2022, with prostate cancer anticipated to remain the most commonly diagnosed type of cancer. The market for clinical trial supplies in North America is therefore being driven by the rising number of cancer cases that are recorded each year. Therefore, for the reasons outlined above, the North American clinical trial supplies market is the largest and is anticipated to develop significantly throughout the projected period. In August 2022, Marken Ltd. (US) purchased Bomi Group to support the expansion of healthcare logistics by expanding the company's international presence and strengthening cold chain capabilities in important European and Latin American markets.

Future Market Scenario (2024-2031F)

One of the main factors contributing to the anticipated growth of the clinical trial supplies market is the increasing demand for clinical trial services to ensure patient safety by delivering the right quality of drugs. The rising population and increasing cases of chronic diseases such as cardiovascular diseases, diabetes, and cancer will also propel the market growth in the forecast period. Players in this market are expanding at an unparalleled rate, introducing cost-effective and efficient technologies. For instance, the IXRS 3 Partnership Network was unveiled by Almac Group Limited (UK) in April 2023 to accelerate developing and implementing cutting-edge eClinical solutions for biopharmaceutical sponsors.

Key Players Landscape and Outlook

Several companies such as Thermo Fisher Scientific Inc., Catalent Inc., Eurofins Scientific, Marken, Parexel, ICON plc, Almac Group Limited, Biocair International Limited, Sharp Services, LLC, Syneos Health, etc., are expanding business by planning and adopting new strategies. They are complying with new strategic initiatives regarding the launches of newly developed clinical trial supplies to help researchers and bring up their market presence. New product launches, agreements based on contracts, acquisitions and mergers, investments, and partnerships are a few ways through which they are trying to achieve the same.

Thermo Fisher Scientific Inc.'s PPD (Pharmaceutical Product Development) clinical research division and Matrix Clinical Trials, a Matrix Medical Network service, joined forces in April 2022 to provide patients with clinical trials through a cutting-edge decentralized clinical trial (DCT) solution.

ASLAN Pharmaceuticals and Thermo Fisher Scientific Inc. partnered in January 2023 to produce an Eblasakimab formulation at a high concentration for future research. Thermo Fisher Scientific will supervise a clinical supply of Eblasakimab for the planned Phase 3 trials by providing its biologic manufacturing knowledge and scale-up capability.

Table of Contents

1. Research Methodology

2. Project Scope & Definitions

3. Executive Summary

4. Global Clinical Trial Supplies Market Outlook, 2017-2031F

  • 4.1. Market Size & Forecast
    • 4.1.1. By Value
  • 4.2. By Service Type
    • 4.2.1. Logistics and Distribution
    • 4.2.2. Storage and Retention
    • 4.2.3. Packaging and Labelling
    • 4.2.4. Manufacturing
    • 4.2.5. Comparator Sourcing
    • 4.2.6. Others
  • 4.3. By Type
    • 4.3.1. Small-Molecule Drugs
    • 4.3.2. Biologic Drugs
    • 4.3.3. Medical Devices
  • 4.4. By Therapeutic Area
    • 4.4.1. Oncology
    • 4.4.2. Neurology
    • 4.4.3. Infectious Diseases
    • 4.4.4. Metabolic Disorders
    • 4.4.5. Immunology
    • 4.4.6. Cardiology
    • 4.4.7. Genetic and Rare Diseases
    • 4.4.8. Others
  • 4.5. By Phase
    • 4.5.1. Phase I
    • 4.5.2. Phase II
    • 4.5.3. Phase III
    • 4.5.4. Phase IV
  • 4.6. By End-user
    • 4.6.1. Pharmaceutical Companies
    • 4.6.2. Biotechnology Companies
    • 4.6.3. Medical Devices Companies
    • 4.6.4. Research Contract Companies
  • 4.7. By Region
    • 4.7.1. North America
    • 4.7.2. Europe
    • 4.7.3. Asia-Pacific
    • 4.7.4. South America
    • 4.7.5. Middle East and Africa
  • 4.8. By Company Market Share (%), 2023

5. Global Clinical Trial Supplies Market Outlook, By Region, 2017-2031F

  • 5.1. North America*
    • 5.1.1. Market Size & Forecast
      • 5.1.1.1. By Value
    • 5.1.2. By Product/Service Type
      • 5.1.2.1. Logistics and Distribution
      • 5.1.2.2. Storage and Retention
      • 5.1.2.3. Packaging and Labelling
      • 5.1.2.4. Manufacturing
      • 5.1.2.5. Comparator Sourcing
      • 5.1.2.6. Others
    • 5.1.3. By Type
      • 5.1.3.1. Small-Molecule Drugs
      • 5.1.3.2. Biologic Drugs
      • 5.1.3.3. Medical Devices
    • 5.1.4. By Therapeutic Area
      • 5.1.4.1. Oncology
      • 5.1.4.2. Neurology
      • 5.1.4.3. Infectious Diseases
      • 5.1.4.4. Metabolic Disorders
      • 5.1.4.5. Immunology
      • 5.1.4.6. Cardiology
      • 5.1.4.7. Genetic and Rare Diseases
      • 5.1.4.8. Others
    • 5.1.5. By Phase
      • 5.1.5.1. Phase I
      • 5.1.5.2. Phase II
      • 5.1.5.3. Phase III
      • 5.1.5.4. Phase IV
    • 5.1.6. By End-user
      • 5.1.6.1. Pharmaceutical Companies
      • 5.1.6.2. Biotechnology Companies
      • 5.1.6.3. Medical Devices Companies
      • 5.1.6.4. Research Contract Companies
    • 5.1.7. United States*
      • 5.1.7.1. Market Size & Forecast
        • 5.1.7.1.1. By Value
      • 5.1.7.2. By Product/Service Type
        • 5.1.7.2.1. Logistics and Distribution
        • 5.1.7.2.2. Storage and Retention
        • 5.1.7.2.3. Packaging and Labelling
        • 5.1.7.2.4. Manufacturing
        • 5.1.7.2.5. Comparator Sourcing
        • 5.1.7.2.6. Others
      • 5.1.7.3. By Type
        • 5.1.7.3.1. Small-Molecule Drugs
        • 5.1.7.3.2. Biologic Drugs
        • 5.1.7.3.3. Medical Devices
      • 5.1.7.4. By Therapeutic Area
        • 5.1.7.4.1. Oncology
        • 5.1.7.4.2. Neurology
        • 5.1.7.4.3. Infectious Diseases
        • 5.1.7.4.4. Metabolic Disorders
        • 5.1.7.4.5. Immunology
        • 5.1.7.4.6. Cardiology
        • 5.1.7.4.7. Genetic and Rare Diseases
        • 5.1.7.4.8. Others
      • 5.1.7.5. By Phase
        • 5.1.7.5.1. Phase I
        • 5.1.7.5.2. Phase II
        • 5.1.7.5.3. Phase III
        • 5.1.7.5.4. Phase IV
      • 5.1.7.6. By End-user
        • 5.1.7.6.1. Pharmaceutical Companies
        • 5.1.7.6.2. Biotechnology Companies
        • 5.1.7.6.3. Medical Devices Companies
        • 5.1.7.6.4. Research Contract Companies
    • 5.1.8. Canada
    • 5.1.9. Mexico

All segments will be provided for all regions and countries covered

  • 5.2. Europe
    • 5.2.1. Germany
    • 5.2.2. France
    • 5.2.3. Italy
    • 5.2.4. United Kingdom
    • 5.2.5. Russia
    • 5.2.6. Netherlands
    • 5.2.7. Spain
    • 5.2.8. Turkey
    • 5.2.9. Poland
  • 5.3. Asia-Pacific
    • 5.3.1. India
    • 5.3.2. China
    • 5.3.3. Japan
    • 5.3.4. Australia
    • 5.3.5. Vietnam
    • 5.3.6. South Korea
    • 5.3.7. Indonesia
    • 5.3.8. Philippines
  • 5.4. South America
    • 5.4.1. Brazil
    • 5.4.2. Argentina
  • 5.5. Middle East & Africa
    • 5.5.1. Saudi Arabia
    • 5.5.2. UAE
    • 5.5.3. South Africa

6. Market Mapping, 2023

  • 6.1. By Service Type
  • 6.2. By Type
  • 6.3. By Therapeutic Area
  • 6.4. By Phase
  • 6.5. By End-user
  • 6.6. By Region

7. Macro Environment and Industry Structure

  • 7.1. Demand Supply Analysis
  • 7.2. Import Export Analysis
  • 7.3. Value Chain Analysis
  • 7.4. PESTEL Analysis
    • 7.4.1. Political Factors
    • 7.4.2. Economic System
    • 7.4.3. Social Implications
    • 7.4.4. Technological Advancements
    • 7.4.5. Environmental Impacts
    • 7.4.6. Legal Compliances and Regulatory Policies (Statutory Bodies Included)
  • 7.5. Porter's Five Forces Analysis
    • 7.5.1. Supplier Power
    • 7.5.2. Buyer Power
    • 7.5.3. Substitution Threat
    • 7.5.4. Threat from New Entrant
    • 7.5.5. Competitive Rivalry

8. Market Dynamics

  • 8.1. Growth Drivers
  • 8.2. Growth Inhibitors (Challenges and Restraints)

9. Innovations/Emerging Technologies

10. Key Players Landscape

  • 10.1. Competition Matrix of Top Five Market Leaders
  • 10.2. Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
  • 10.3. Mergers and Acquisitions/Joint Ventures (If Applicable)
  • 10.4. SWOT Analysis (For Five Market Players)
  • 10.5. Patent Analysis (If Applicable)

11. Case Studies

12. Key Players Outlook

  • 12.1. Thermo Fisher Scientific Inc.
    • 12.1.1. Company Details
    • 12.1.2. Key Management Personnel
    • 12.1.3. Products & Services
    • 12.1.4. Financials (As reported)
    • 12.1.5. Key Market Focus & Geographical Presence
    • 12.1.6. Recent Developments
  • 12.2. Catalent Inc.
  • 12.3. Eurofins Scientific
  • 12.4. Marken
  • 12.5. Parexel
  • 12.6. ICON plc
  • 12.7. Almac Group Limited
  • 12.8. Biocair International Limited
  • 12.9. Sharp Services, LLC
  • 12.10. Syneos Health

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

13. Strategic Recommendations

14. About Us & Disclaimer

List of Tables

  • Table 1. Pricing Analysis of Products from Key Players
  • Table 2. Competition Matrix of Top 5 Market Leaders
  • Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1. Global Clinical Trial Supplies Market, By Value, In USD Billion, 2017-2031F
  • Figure 2. Global Clinical Trial Supplies Market Share (%), By Service Type, 2017-2031F
  • Figure 3. Global Clinical Trial Supplies Market Share (%), By Type, 2017-2031F
  • Figure 4. Global Clinical Trial Supplies Market Share (%), By Therapeutic Area, 2017-2031F
  • Figure 5. Global Clinical Trial Supplies Market Share (%), By Phase, 2017-2031F
  • Figure 6. Global Clinical Trial Supplies Market Share (%), By End-user, 2017-2031F
  • Figure 7. Global Clinical Trial Supplies Market Share (%), By Region, 2017-2031F
  • Figure 8. North America Clinical Trial Supplies Market, By Value, In USD Billion, 2017-2031F
  • Figure 9. North America Clinical Trial Supplies Market Share (%), By Service Type, 2017-2031F
  • Figure 10. North America Clinical Trial Supplies Market Share (%), By Type, 2017-2031F
  • Figure 11. North America Clinical Trial Supplies Market Share (%), By Therapeutic Area, 2017-2031F
  • Figure 12. North America Clinical Trial Supplies Market Share (%), By Phase, 2017-2031F
  • Figure 13. North America Clinical Trial Supplies Market Share (%), By End-user, 2017-2031F
  • Figure 14. North America Clinical Trial Supplies Market Share (%), By Country, 2017-2031F
  • Figure 15. United States Clinical Trial Supplies Market, By Value, In USD Billion, 2017-2031F
  • Figure 16. United States Clinical Trial Supplies Market Share (%), By Service Type, 2017-2031F
  • Figure 17. United States Clinical Trial Supplies Market Share (%), By Type, 2017-2031F
  • Figure 18. United States Clinical Trial Supplies Market Share (%), By Therapeutic Area, 2017-2031F
  • Figure 19. United States Clinical Trial Supplies Market Share (%), By Phase, 2017-2031F
  • Figure 20. United States Clinical Trial Supplies Market Share (%), By End-user, 2017-2031F
  • Figure 21. Canada Clinical Trial Supplies Market, By Value, In USD Billion, 2017-2031F
  • Figure 22. Canada Clinical Trial Supplies Market Share (%), By Service Type, 2017-2031F
  • Figure 23. Canada Clinical Trial Supplies Market Share (%), By Type, 2017-2031F
  • Figure 24. Canada Clinical Trial Supplies Market Share (%), By Therapeutic Area, 2017-2031F
  • Figure 25. Canada Clinical Trial Supplies Market Share (%), By Phase, 2017-2031F
  • Figure 26. Canada Clinical Trial Supplies Market Share (%), By End-user, 2017-2031F
  • Figure 27. Mexico Clinical Trial Supplies Market, By Value, In USD Billion, 2017-2031F
  • Figure 28. Mexico Clinical Trial Supplies Market Share (%), By Service Type, 2017-2031F
  • Figure 29. Mexico Clinical Trial Supplies Market Share (%), By Type, 2017-2031F
  • Figure 30. Mexico Clinical Trial Supplies Market Share (%), By Therapeutic Area, 2017-2031F
  • Figure 31. Mexico Clinical Trial Supplies Market Share (%), By Phase, 2017-2031F
  • Figure 32. Mexico Clinical Trial Supplies Market Share (%), By End-user, 2017-2031F
  • Figure 33. Europe Clinical Trial Supplies Market, By Value, In USD Billion, 2017-2031F
  • Figure 34. Europe Clinical Trial Supplies Market Share (%), By Service Type, 2017-2031F
  • Figure 35. Europe Clinical Trial Supplies Market Share (%), By Type, 2017-2031F
  • Figure 36. Europe Clinical Trial Supplies Market Share (%), By Therapeutic Area, 2017-2031F
  • Figure 37. Europe Clinical Trial Supplies Market Share (%), By Phase, 2017-2031F
  • Figure 38. Europe Clinical Trial Supplies Market Share (%), By End-user, 2017-2031F
  • Figure 39. Europe Clinical Trial Supplies Market Share (%), By Country, 2017-2031F
  • Figure 40. Germany Clinical Trial Supplies Market, By Value, In USD Billion, 2017-2031F
  • Figure 41. Germany Clinical Trial Supplies Market Share (%), By Service Type, 2017-2031F
  • Figure 42. Germany Clinical Trial Supplies Market Share (%), By Type, 2017-2031F
  • Figure 43. Germany Clinical Trial Supplies Market Share (%), By Therapeutic Area, 2017-2031F
  • Figure 44. Germany Clinical Trial Supplies Market Share (%), By Phase, 2017-2031F
  • Figure 45. Germany Clinical Trial Supplies Market Share (%), By End-user, 2017-2031F
  • Figure 46. France Clinical Trial Supplies Market, By Value, In USD Billion, 2017-2031F
  • Figure 47. France Clinical Trial Supplies Market Share (%), By Service Type, 2017-2031F
  • Figure 48. France Clinical Trial Supplies Market Share (%), By Type, 2017-2031F
  • Figure 49. France Clinical Trial Supplies Market Share (%), By Therapeutic Area, 2017-2031F
  • Figure 50. France Clinical Trial Supplies Market Share (%), By Phase, 2017-2031F
  • Figure 51. France Clinical Trial Supplies Market Share (%), By End-user, 2017-2031F
  • Figure 52. Italy Clinical Trial Supplies Market, By Value, In USD Billion, 2017-2031F
  • Figure 53. Italy Clinical Trial Supplies Market Share (%), By Service Type, 2017-2031F
  • Figure 54. Italy Clinical Trial Supplies Market Share (%), By Type, 2017-2031F
  • Figure 55. Italy Clinical Trial Supplies Market Share (%), By Therapeutic Area, 2017-2031F
  • Figure 56. Italy Clinical Trial Supplies Market Share (%), By Phase, 2017-2031F
  • Figure 57. Italy Clinical Trial Supplies Market Share (%), By End-user, 2017-2031F
  • Figure 58. United Kingdom Clinical Trial Supplies Market, By Value, In USD Billion, 2017-2031F
  • Figure 59. United Kingdom Clinical Trial Supplies Market Share (%), By Service Type, 2017-2031F
  • Figure 60. United Kingdom Clinical Trial Supplies Market Share (%), By Type, 2017-2031F
  • Figure 61. United Kingdom Clinical Trial Supplies Market Share (%), By Therapeutic Area, 2017-2031F
  • Figure 62. United Kingdom Clinical Trial Supplies Market Share (%), By Phase, 2017-2031F
  • Figure 63. United Kingdom Clinical Trial Supplies Market Share (%), By End-user, 2017-2031F
  • Figure 64. Russia Clinical Trial Supplies Market, By Value, In USD Billion, 2017-2031F
  • Figure 65. Russia Clinical Trial Supplies Market Share (%), By Service Type, 2017-2031F
  • Figure 66. Russia Clinical Trial Supplies Market Share (%), By Type, 2017-2031F
  • Figure 67. Russia Clinical Trial Supplies Market Share (%), By Therapeutic Area, 2017-2031F
  • Figure 68. Russia Clinical Trial Supplies Market Share (%), By Phase, 2017-2031F
  • Figure 69. Russia Clinical Trial Supplies Market Share (%), By End-user, 2017-2031F
  • Figure 70. Netherlands Clinical Trial Supplies Market, By Value, In USD Billion, 2017-2031F
  • Figure 71. Netherlands Clinical Trial Supplies Market Share (%), By Service Type, 2017-2031F
  • Figure 72. Netherlands Clinical Trial Supplies Market Share (%), By Type, 2017-2031F
  • Figure 73. Netherlands Clinical Trial Supplies Market Share (%), By Therapeutic Area, 2017-2031F
  • Figure 74. Netherlands Clinical Trial Supplies Market Share (%), By Phase, 2017-2031F
  • Figure 75. Netherlands Clinical Trial Supplies Market Share (%), By End-user, 2017-2031F
  • Figure 76. Spain Clinical Trial Supplies Market, By Value, In USD Billion, 2017-2031F
  • Figure 77. Spain Clinical Trial Supplies Market Share (%), By Service Type, 2017-2031F
  • Figure 78. Spain Clinical Trial Supplies Market Share (%), By Type, 2017-2031F
  • Figure 79. Spain Clinical Trial Supplies Market Share (%), By Therapeutic Area, 2017-2031F
  • Figure 80. Spain Clinical Trial Supplies Market Share (%), By Phase, 2017-2031F
  • Figure 81. Spain Clinical Trial Supplies Market Share (%), By End-user, 2017-2031F
  • Figure 82. Turkey Clinical Trial Supplies Market, By Value, In USD Billion, 2017-2031F
  • Figure 83. Turkey Clinical Trial Supplies Market Share (%), By Service Type, 2017-2031F
  • Figure 84. Turkey Clinical Trial Supplies Market Share (%), By Type, 2017-2031F
  • Figure 85. Turkey Clinical Trial Supplies Market Share (%), By Therapeutic Area, 2017-2031F
  • Figure 86. Turkey Clinical Trial Supplies Market Share (%), By Phase, 2017-2031F
  • Figure 87. Turkey Clinical Trial Supplies Market Share (%), By End-user, 2017-2031F
  • Figure 88. Poland Clinical Trial Supplies Market, By Value, In USD Billion, 2017-2031F
  • Figure 89. Poland Clinical Trial Supplies Market Share (%), By Service Type, 2017-2031F
  • Figure 90. Poland Clinical Trial Supplies Market Share (%), By Type, 2017-2031F
  • Figure 91. Poland Clinical Trial Supplies Market Share (%), By Therapeutic Area, 2017-2031F
  • Figure 92. Poland Clinical Trial Supplies Market Share (%), By Phase, 2017-2031F
  • Figure 93. Poland Clinical Trial Supplies Market Share (%), By End-user, 2017-2031F
  • Figure 94. South America Clinical Trial Supplies Market, By Value, In USD Billion, 2017-2031F
  • Figure 95. South America Clinical Trial Supplies Market Share (%), By Service Type, 2017-2031F
  • Figure 96. South America Clinical Trial Supplies Market Share (%), By Type, 2017-2031F
  • Figure 97. South America Clinical Trial Supplies Market Share (%), By Therapeutic Area, 2017-2031F
  • Figure 98. South America Clinical Trial Supplies Market Share (%), By Phase, 2017-2031F
  • Figure 99. South America Clinical Trial Supplies Market Share (%), By End-user, 2017-2031F
  • Figure 100. South America Clinical Trial Supplies Market Share (%), By Country, 2017-2031F
  • Figure 101. Brazil Clinical Trial Supplies Market, By Value, In USD Billion, 2017-2031F
  • Figure 102. Brazil Clinical Trial Supplies Market Share (%), By Service Type, 2017-2031F
  • Figure 103. Brazil Clinical Trial Supplies Market Share (%), By Type, 2017-2031F
  • Figure 104. Brazil Clinical Trial Supplies Market Share (%), By Therapeutic Area, 2017-2031F
  • Figure 105. Brazil Clinical Trial Supplies Market Share (%), By Phase, 2017-2031F
  • Figure 106. Brazil Clinical Trial Supplies Market Share (%), By End-user, 2017-2031F
  • Figure 107. Argentina Clinical Trial Supplies Market, By Value, In USD Billion, 2017-2031F
  • Figure 108. Argentina Clinical Trial Supplies Market Share (%), By Service Type, 2017-2031F
  • Figure 109. Argentina Clinical Trial Supplies Market Share (%), By Type, 2017-2031F
  • Figure 110. Argentina Clinical Trial Supplies Market Share (%), By Therapeutic Area, 2017-2031F
  • Figure 111. Argentina Clinical Trial Supplies Market Share (%), By Phase, 2017-2031F
  • Figure 112. Argentina Clinical Trial Supplies Market Share (%), By End-user, 2017-2031F
  • Figure 113. Asia-Pacific Clinical Trial Supplies Market, By Value, In USD Billion, 2017-2031F
  • Figure 114. Asia-Pacific Clinical Trial Supplies Market Share (%), By Service Type, 2017-2031F
  • Figure 115. Asia-Pacific Clinical Trial Supplies Market Share (%), By Type, 2017-2031F
  • Figure 116. Asia-Pacific Clinical Trial Supplies Market Share (%), By Therapeutic Area, 2017-2031F
  • Figure 117. Asia-Pacific Clinical Trial Supplies Market Share (%), By Phase, 2017-2031F
  • Figure 118. Asia-Pacific Clinical Trial Supplies Market Share (%), By End-user, 2017-2031F
  • Figure 119. Asia-Pacific Clinical Trial Supplies Market Share (%), By Country, 2017-2031F
  • Figure 120. India Clinical Trial Supplies Market, By Value, In USD Billion, 2017-2031F
  • Figure 121. India Clinical Trial Supplies Market Share (%), By Service Type, 2017-2031F
  • Figure 122. India Clinical Trial Supplies Market Share (%), By Type, 2017-2031F
  • Figure 123. India Clinical Trial Supplies Market Share (%), By Therapeutic Area, 2017-2031F
  • Figure 124. India Clinical Trial Supplies Market Share (%), By Phase, 2017-2031F
  • Figure 125. India Clinical Trial Supplies Market Share (%), By End-user, 2017-2031F
  • Figure 126. China Clinical Trial Supplies Market, By Value, In USD Billion, 2017-2031F
  • Figure 127. China Clinical Trial Supplies Market Share (%), By Service Type, 2017-2031F
  • Figure 128. China Clinical Trial Supplies Market Share (%), By Type, 2017-2031F
  • Figure 129. China Clinical Trial Supplies Market Share (%), By Therapeutic Area, 2017-2031F
  • Figure 130. China Clinical Trial Supplies Market Share (%), By Phase, 2017-2031F
  • Figure 131. China Clinical Trial Supplies Market Share (%), By End-user, 2017-2031F
  • Figure 132. Japan Clinical Trial Supplies Market, By Value, In USD Billion, 2017-2031F
  • Figure 133. Japan Clinical Trial Supplies Market Share (%), By Service Type, 2017-2031F
  • Figure 134. Japan Clinical Trial Supplies Market Share (%), By Type, 2017-2031F
  • Figure 135. Japan Clinical Trial Supplies Market Share (%), By Therapeutic Area, 2017-2031F
  • Figure 136. Japan Clinical Trial Supplies Market Share (%), By Phase, 2017-2031F
  • Figure 137. Japan Clinical Trial Supplies Market Share (%), By End-user, 2017-2031F
  • Figure 138. Australia Clinical Trial Supplies Market, By Value, In USD Billion, 2017-2031F
  • Figure 139. Australia Clinical Trial Supplies Market Share (%), By Service Type, 2017-2031F
  • Figure 140. Australia Clinical Trial Supplies Market Share (%), By Type, 2017-2031F
  • Figure 141. Australia Clinical Trial Supplies Market Share (%), By Therapeutic Area, 2017-2031F
  • Figure 142. Australia Clinical Trial Supplies Market Share (%), By Phase, 2017-2031F
  • Figure 143. Australia Clinical Trial Supplies Market Share (%), By End-user, 2017-2031F
  • Figure 144. Vietnam Clinical Trial Supplies Market, By Value, In USD Billion, 2017-2031F
  • Figure 145. Vietnam Clinical Trial Supplies Market Share (%), By Service Type, 2017-2031F
  • Figure 146. Vietnam Clinical Trial Supplies Market Share (%), By Type, 2017-2031F
  • Figure 147. Vietnam Clinical Trial Supplies Market Share (%), By Therapeutic Area, 2017-2031F
  • Figure 148. Vietnam Clinical Trial Supplies Market Share (%), By Phase, 2017-2031F
  • Figure 149. Vietnam Clinical Trial Supplies Market Share (%), By End-user, 2017-2031F
  • Figure 150. South Korea Clinical Trial Supplies Market, By Value, In USD Billion, 2017-2031F
  • Figure 151. South Korea Clinical Trial Supplies Market Share (%), By Service Type, 2017-2031F
  • Figure 152. South Korea Clinical Trial Supplies Market Share (%), By Type, 2017-2031F
  • Figure 153. South Korea Clinical Trial Supplies Market Share (%), By Therapeutic Area, 2017-2031F
  • Figure 154. South Korea Clinical Trial Supplies Market Share (%), By Phase, 2017-2031F
  • Figure 155. South Korea Clinical Trial Supplies Market Share (%), By End-user, 2017-2031F
  • Figure 156. Indonesia Clinical Trial Supplies Market, By Value, In USD Billion, 2017-2031F
  • Figure 157. Indonesia Clinical Trial Supplies Market Share (%), By Service Type, 2017-2031F
  • Figure 158. Indonesia Clinical Trial Supplies Market Share (%), By Type, 2017-2031F
  • Figure 159. Indonesia Clinical Trial Supplies Market Share (%), By Therapeutic Area, 2017-2031F
  • Figure 160. Indonesia Clinical Trial Supplies Market Share (%), By Phase, 2017-2031F
  • Figure 161. Indonesia Clinical Trial Supplies Market Share (%), By End-user, 2017-2031F
  • Figure 162. Philippines Clinical Trial Supplies Market, By Value, In USD Billion, 2017-2031F
  • Figure 163. Philippines Clinical Trial Supplies Market Share (%), By Service Type, 2017-2031F
  • Figure 164. Philippines Clinical Trial Supplies Market Share (%), By Type, 2017-2031F
  • Figure 165. Philippines Clinical Trial Supplies Market Share (%), By Therapeutic Area, 2017-2031F
  • Figure 166. Philippines Clinical Trial Supplies Market Share (%), By Phase, 2017-2031F
  • Figure 167. Philippines Clinical Trial Supplies Market Share (%), By End-user, 2017-2031F
  • Figure 168. Middle East & Africa Clinical Trial Supplies Market, By Value, In USD Billion, 2017-2031F
  • Figure 169. Middle East & Africa Clinical Trial Supplies Market Share (%), By Service Type, 2017-2031F
  • Figure 170. Middle East & Africa Clinical Trial Supplies Market Share (%), By Type, 2017-2031F
  • Figure 171. Middle East & Africa Clinical Trial Supplies Market Share (%), By Therapeutic Area, 2017-2031F
  • Figure 172. Middle East & Africa Clinical Trial Supplies Market Share (%), By Phase, 2017-2031F
  • Figure 173. Middle East & Africa Clinical Trial Supplies Market Share (%), By End-user, 2017-2031F
  • Figure 174. Middle East & Africa Clinical Trial Supplies Market Share (%), By Country, 2017-2031F
  • Figure 175. Saudi Arabia Clinical Trial Supplies Market, By Value, In USD Billion, 2017-2031F
  • Figure 176. Saudi Arabia Clinical Trial Supplies Market Share (%), By Service Type, 2017-2031F
  • Figure 177. Saudi Arabia Clinical Trial Supplies Market Share (%), By Type, 2017-2031F
  • Figure 178. Saudi Arabia Clinical Trial Supplies Market Share (%), By Therapeutic Area, 2017-2031F
  • Figure 179. Saudi Arabia Clinical Trial Supplies Market Share (%), By Phase, 2017-2031F
  • Figure 180. Saudi Arabia Clinical Trial Supplies Market Share (%), By End-user, 2017-2031F
  • Figure 181. UAE Clinical Trial Supplies Market, By Value, In USD Billion, 2017-2031F
  • Figure 182. UAE Clinical Trial Supplies Market Share (%), By Service Type, 2017-2031F
  • Figure 183. UAE Clinical Trial Supplies Market Share (%), By Type, 2017-2031F
  • Figure 184. UAE Clinical Trial Supplies Market Share (%), By Therapeutic Area, 2017-2031F
  • Figure 185. UAE Clinical Trial Supplies Market Share (%), By Phase, 2017-2031F
  • Figure 186. UAE Clinical Trial Supplies Market Share (%), By End-user, 2017-2031F
  • Figure 187. South Africa Clinical Trial Supplies Market, By Value, In USD Billion, 2017-2031F
  • Figure 188. South Africa Clinical Trial Supplies Market Share (%), By Service Type, 2017-2031F
  • Figure 189. South Africa Clinical Trial Supplies Market Share (%), By Type, 2017-2031F
  • Figure 190. South Africa Clinical Trial Supplies Market Share (%), By Therapeutic Area, 2017-2031F
  • Figure 191. South Africa Clinical Trial Supplies Market Share (%), By Phase, 2017-2031F
  • Figure 192. South Africa Clinical Trial Supplies Market Share (%), By End-user, 2017-2031F
  • Figure 193. By Service Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 194. By Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 195. By Therapeutic Area Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 196. By Phase Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 197. By End-user Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 198. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023